LMF Acquisition Opportunities

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company was founded on June 6, 2007 and is headquartered in Denver, CO.

LMF Acquisition Opportunities Renamed SeaStar Medical Holding Corporation

SeaStar Medical Completes Business Combination with LMF Acquisition Opportunities

To be honest, LMF Acquisition Opportunities (NASDAQ: LMAO ) is really just a shell company. However, it's getting a lot of attention today, and LMAO stock is surging higher.

LMAO Stock Surges as Shareholders Approve SeaStar Medical Merger

Transaction anticipated to close upon satisfaction of all closing conditions Transaction anticipated to close upon satisfaction of all closing conditions

LMF Acquisition Opportunities, Inc. Stockholders Approve Previously Announced Business Combination with SeaStar Medical, Inc.

All stockholders of LMF Acquisition Opportunities as of September 23, 2022 are encouraged to vote their shares as soon as possible before the special meeting

LMF Acquisition Opportunities and SeaStar Medical Announce Effectiveness of Registration Statement and Special Meeting of Stockholders to be Held October 18, 2022 to Approve Business Combination

Denver, Colo. and Tampa, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced the appointment of Dr. Sai Prasad N. Iyer, Ph.D to the position of Vice President, Medical Affairs and Clinical Development at SeaStar Medical, effective September 15, 2022.

SeaStar Medical Appoints Dr. Sai Prasad Iyer, Ph.D as VP, Medical Affairs and Clinical Development

Case report published in peer-reviewed journal, Pediatric Nephrology Case report published in peer-reviewed journal, Pediatric Nephrology

SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD

TAMPA, FL, July 29, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (the “Company”) announced today that its board of directors has elected to extend the date by which the Company has to consummate a business combination from July 29, 2022 to October 29, 2022 (the “Extension”), as permitted under the Company's Amended and Restated Certificate of Incorporation. In connection with the Extension, the Company's sponsor, LMFAO Sponsor, LLC, has notified the Company that it intends to deposit an aggregate of $1,035,000 (representing $0.10 per public share) into the Company's trust account on or before July 29, 2022. The Extension provides the Company with additional time to complete its proposed business combination with SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs.

LMF Acquisition Opportunities, Inc. Announces Extension of Deadline to Complete Business Combination

Application follows successful pilot study demonstrating the SCD was safe with probable clinical benefits for pediatric patients Application follows successful pilot study demonstrating the SCD was safe with probable clinical benefits for pediatric patients

SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury

Results published in the Society of Critical Care Management's journal, Critical Care Explorations Results published in the Society of Critical Care Management's journal, Critical Care Explorations

SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms

TAMPA, Fla.--(BUSINESS WIRE)--Skyway Capital Markets, LLC (“Skyway”) is pleased to announce the merger of SeaStar Medical, Inc. (“SeaStar Medical”), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a publicly traded special purpose acquisition company. Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection

Skyway Capital Markets Advises SPAC on $85 Million Medical Technology Merger

CDK Global

Meritor

Tenneco

TEGNA

NEW YORK , April 25, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CDK Global, Inc. (NASDAQ: CDK)'s  sale to Brookfield Business Partners and its institutional partners for $54.87 per share in cash. If you are a CDK shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CDK, TGNA, LMAO, MTOR, TEN

SeaStar Medical Inc, a medical tech corporation focusing on the development of extracorporeal therapy treatments to reduce the symptoms of vital organ inflammation, is merging with LMF Acquisition Opportunities Inc (NASDAQ: LMAO), a publicly trading special purpose acquisition business, to get a NASDAQ trading listing. The merger agreement is expected to give SeaStar access to the capital market.

SeaStar Medical is getting NASDAQ listing via a merger with LMAO

DENVER and TAMPA, Fla., April 22, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc. (“SeaStar Medical”), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a publicly traded special purpose acquisition company, today announced they have entered into a merger agreement. The transaction is expected to provide SeaStar Medical with access to the capital markets and thereby position the company to accelerate the development and advancement of its lead programs for acute kidney injury (AKI) in both pediatric and adult patients, as well as advance other SeaStar Medical programs in acute and chronic indications.

SeaStar Medical to Become Publicly Listed on Nasdaq via Business Combination with LMF Acquisition Opportunities, Inc.

News for LMF Acquisition Opportunities Stock (LMAO)